Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example input: "Although the story didn’t cite the cost of appendectomy – emergency or urgent surgery – and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn’t give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients’ condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn’t give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients’ condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story – and one we applaud – when it begins:  ""Appendectomy is the most common emergency surgery in the world, but it doesn’t have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn’t include any fresh quotes from interviews, we can’t be sure of the extent to which it may have been influenced by a news release."
Example output: Some appendicitis cases may not require ’emergency’ surgery
Example explanation: The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn’t have to be." which is considered evidence for the output. Thus, the output is a valid claim.
Q: The story takes the rare step of talking about costs from three different angles. The cost to the physician. The cost to the patient. And the cost to insursers. “Doctors will pay a one-time fee of $7,500 to lease and receive training on the device. Patients will pay $150 out of pocket for a MelaFind scan, which analysts say may limit use to more affluent patients who are willing to pay extra for the latest medical care. Mela Sciences does not plan to ask insurers to cover the device until several years from now, after it is more widely used. The story shows that the device is fairly effective at finding cancerous lesions. “In a company-sponsored study published last year involving around 1,300 patients, some with multiple growths, doctors reported that MelaFind correctly suggested biopsies on 125 of 127 melanomas that doctors had removed.” It’s a bit confusing, but the story explains that the device also makes the wrong call too often, giving too many false positives. “However, the device did not raise an alarm about non-melanoma growths only about 10 percent of the time; that was still better than doctors in the study who correctly ruled out melanoma in less than 4 percent of such cases, on average.” Just presenting the false positive and false negative rates would have been more helpful to readers. We would have liked to have seen a little more about the latest study of the device, but there was enough information in the story to let readers know that this is the case where the evidence is still not quite settled. It says, for example, “MelaFind underwent a contentious, years-long review by the Food and Drug Administration, which initially rejected the device and concluded it could ‘potentially cause more harm than good. '” And later it says that “an FDA-required follow-up study would help determine how much of a benefit MelaFind represents for patients.” The story both gives the broader context about melanoma while taking care to pinpoint the appropriate patient population. It says in the second paragraph, “The device is approved only for dermatologists and only for use on growths that don’t have obvious signs of cancer but still have one or two worrisome traits.” It also says, “Nearly all patients diagnosed with early-stage melanoma can be treated and cured, but 85 percent of patients with late-stage melanoma die from it within five years.” The story could have more clearly stated that while many are diagnosed with melanoma only a small number actually will die from it. The late stage cases are a small fraction of the total. The story does not use a truly independent source because everyone appears to have some sort of conflict, but this is also one of the stories strengths. Rarely have we seen conflicts presented with this kind of detail. For example, the story says describes Dr. Leonard Goldberg as “a dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.” The story compares the device to clinicians throughout, and shows clearly that dermatologists are still the ones with the best authority in this area. The story says clearly that the devices are not currently available in most areas. “But don’t expect to see a MelaFind machine at your next doctor’s appointment. The company plans a limited rollout next year of just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.” The story calls the device a “first of its kind,” but it also explains that it is only approved for use in a subset of patients and that much more work needs to be done. The story does not rely on a news release.
A:

Show your work and conclude with the exact phrasing "Therefore, the final answer is [answer]." where [answer] is just the final number or expression that solves the problem.
user
New device uses light to screen for melanoma